IP Verse

Zentiva K.s. opposition analysis

COMPANY ANALYSIS

Latest oppositions filed by Zentiva K.s.

Patent Number:
EP3626270
Title:
New Use
Applicant:
NOVARTIS AG
Opposition Date:
Jul 11, 2024
Patent Number:
EP2981255
Title:
Therapeutic Uses Of Empagliflozin
Applicant:
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
Opposition Date:
Jun 13, 2023
Patent Number:
EP2959894
Title:
S1P Receptor Modulators For Treating Multiple Sclerosis
Applicant:
NOVARTIS AG
Opposition Date:
Oct 12, 2022
Patent Number:
EP2653873
Title:
Compositions And Uses For Treating Multiple Sclerosis
Applicant:
BIOGEN IDEC MA INC.
Opposition Date:
Sep 23, 2022
Patent Number:
EP3725778
Title:
Formulations Of Enzalutamide
Applicant:
ASTELLAS PHARMA INC.
Opposition Date:
May 13, 2022
Patent Number:
EP3053580
Title:
Method Of Providing Pirfenidone Therapy To A Patient
Applicant:
INTERMUNE, INC.
Opposition Date:
Mar 30, 2022
Patent Number:
EP2234617
Title:
Dosing Regimen Associated With Long Acting Injectable Paliperidone Esters
Applicant:
JANSSEN PHARMACEUTICA NV
Opposition Date:
Dec 31, 2021
Patent Number:
EP2478907
Title:
Methods And Compositions For Treating Cancer
Applicant:
COUGAR BIOTECHNOLOGY, INC.
Opposition Date:
Jun 2, 2021
Patent Number:
EP2493466
Title:
Novel Antitumoral Use Of Cabazitaxel
Applicant:
AVENTIS PHARMA S.A.
Opposition Date:
Mar 12, 2021
Patent Number:
EP3127427
Title:
Methods Of Administration Of Thrombopoietin Agonist Compounds
Applicant:
NOVARTIS AG
Opposition Date:
Oct 8, 2020

Competitors of Zentiva K.s.

NOVARTIS AG

BRISTOL-MYERS SQUIBB HOLDINGS IRELAND

BRISTOL-MYERS SQUIBB HOLDINGS IRELAND UNLIMITED COMPANY

Want to track Zentiva K.s.?

Feel free to send us a message here and we will get back to you